CME Latest Quarter's Earnings
| Announce Date | 02/04/2026 |
| EPS Normalized Actual | $2.77 (Beat by $0.02) |
| EPS GAAP Actual | $2.77 (Beat by $0.02) |
| Revenue Actual | $1.5376B |
| Revenue Surprise | Beat by $1537.6M |
Upcoming Quarter's Earnings
| Announce Date | 03/31/2026 (Pre-Market) |
| EPS Normalized Estimate | $2.72 |
| EPS GAAP Estimate | $2.72 |
| Revenue Estimate | $1.65B |
Annual EPS Estimate
| Fiscal Period Ending | EPS Estimate | Forward PE | Low | High | # of Analysts |
|---|---|---|---|---|---|
| Dec 2030 | 14.09 | 21.45 | 13.4956 | 14.62913 | 1 |
| Dec 2029 | 13.55 | 22.31 | 12.82722 | 13.98569 | 1 |
Quarterly EPS History
| Period | EPS | Beat / Miss | Revenue | YoY | Beat / Miss |
|---|---|---|---|---|---|
| FQ3 2025 (Sep 2025) | 2.49 | 2.49 | 1.5376B | -3.04% | 1537.6M |
| FQ2 2025 (Jun 2025) | 2.81 | 2.81 | 1.692B | 9.43% | 1692M |
| FQ1 2025 (Mar 2025) | 2.63 | 2.63 | 1.6423B | 9.4% | 1642.3M |
| FQ4 2024 (Dec 2024) | 2.4 | 2.4 | 1.5253B | 5.64% | 1525.3M |
| FQ3 2024 (Sep 2024) | 2.45 | 2.45 | 1.5844B | 15.56% | 1584.4M |
| FQ2 2024 (Jun 2024) | 2.43 | 2.43 | 1.5325B | 11.24% | 1532.5M |
| FQ1 2024 (Mar 2024) | 2.35 | 2.35 | 1.4879B | 3.11% | 1487.9M |
| FQ4 2023 (Dec 2023) | 2.24 | 2.24 | 1.4393B | 16.08% | 1439.3M |
Quarterly Estimates Summary
FQ4 Announce Date
03/31/2026 (Pre-Market)
Consensus EPS Estimates
2.72
Consensus Revenue Estimates
1.65B
Consensus EPS Estimates
| Fiscal Period Ending | EPS Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ3 2029 (Sep 2029) | 3.5 | -- | 3.39223 | 3.68029 | 6 |
| FQ2 2029 (Jun 2029) | 3.58 | -- | 3.46977 | 3.76441 | 3 |
| FQ1 2029 (Mar 2029) | 3.65 | -- | 3.53762 | 3.83802 | 3 |
| FQ3 2028 (Sep 2028) | 3.6 | -- | 3.48916 | 3.78544 | 6 |
| FQ2 2028 (Jun 2028) | 3.67 | -- | 3.557 | 3.85905 | 4 |
| FQ1 2028 (Mar 2028) | 3.72 | -- | 3.60546 | 3.91162 | 4 |
| FQ4 2027 (Dec 2027) | 2.89 | -- | 2.67124 | 3.08297 | 4 |
| FQ3 2027 (Sep 2027) | 3.04 | -- | 2.80988 | 3.24298 | 7 |
| FQ2 2027 (Jun 2027) | 2.98 | -- | 2.75442 | 3.17898 | 4 |
| FQ1 2027 (Mar 2027) | 2.88 | -- | 2.66199 | 3.0723 | 4 |
| FQ4 2026 (Oct 2026) | 2.56 | -- | 2.41438 | 2.78475 | 7 |
| FQ3 2026 (Jul 2026) | 2.65 | 6.04 | 2.49926 | 2.88265 | 4 |
| FQ2 2026 (Jun 2026) | 2.65 | -6.04 | 2.4763 | 2.79887 | 4 |
| FQ1 2026 (Mar 2026) | 2.72 | 3.31 | 2.56528 | 2.95879 | 4 |
Consensus Revenue Estimates
| Fiscal Period Ending | Revenue Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ3 2029 (Sep 2029) | 2.09B | -- | 2.04B | 2.17B | 3 |
| FQ2 2029 (Jun 2029) | 2.12B | -- | 2.07B | 2.21B | 3 |
| FQ1 2029 (Mar 2029) | 2.15B | -- | 2.1B | 2.23B | 5 |
| FQ3 2028 (Sep 2028) | 2B | -- | 1.95B | 2.08B | 4 |
| FQ2 2028 (Jun 2028) | 2.03B | -- | 1.99B | 2.11B | 5 |
| FQ1 2028 (Mar 2028) | 2.06B | -- | 2.01B | 2.14B | 2 |
| FQ4 2027 (Dec 2027) | 1.7B | -- | 1.6B | 1.78B | 9 |
| FQ3 2027 (Sep 2027) | 1.71B | -- | 1.61B | 1.8B | 9 |
| FQ2 2027 (Jun 2027) | 1.7B | -- | 1.6B | 1.79B | 9 |
| FQ1 2027 (Mar 2027) | 1.67B | -- | 1.57B | 1.75B | 9 |
| FQ4 2026 (Oct 2026) | 1.61B | -- | 1.54B | 1.72B | 5 |
| FQ3 2026 (Jul 2026) | 1.61B | 4.5 | 1.54B | 1.72B | 5 |
| FQ2 2026 (Jun 2026) | 1.61B | -5.09 | 1.53B | 1.68B | 5 |
| FQ1 2026 (Mar 2026) | 1.65B | 0.47 | 1.58B | 1.76B | 5 |
Quarterly Estimates Revisions
EPS # of Up Revisions
4
EPS # of Down Revisions
4
Revenue # of Up Revisions
6
Revenue # of Down Revisions
3
Consensus EPS Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Consensus Revenue Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Earnings Surprise Summary
EPS # of Beats
8
EPS # of Misses
0
EPS # of in-lines
0
Revenue # of Beats
8
Revenue # of Misses
0
Revenue # of in-lines
0
Earnings Surprise (EPS) - Actual vs Consensus
| Earnings Date | EPS Estimate | EPS Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ3 2025 (Sep 2025) | 2.49 | 2.49 | 100% | |
| FQ2 2025 (Jun 2025) | 2.81 | 2.81 | 100% | |
| FQ1 2025 (Mar 2025) | 2.63 | 2.63 | 100% | |
| FQ4 2024 (Dec 2024) | 2.4 | 2.4 | 100% | |
| FQ3 2024 (Sep 2024) | 2.45 | 2.45 | 100% | |
| FQ2 2024 (Jun 2024) | 2.43 | 2.43 | 100% | |
| FQ1 2024 (Mar 2024) | 2.35 | 2.35 | 100% | |
| FQ4 2023 (Dec 2023) | 2.24 | 2.24 | 100% |
Revenue Surprise - Actual vs Consensus
| Earnings Date | Revenue Estimate | Revenue Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ3 2025 (Sep 2025) | $0B | $1.54B | $1537.6M | 100% |
| FQ2 2025 (Jun 2025) | $0B | $1.69B | $1692M | 100% |
| FQ1 2025 (Mar 2025) | $0B | $1.64B | $1642.3M | 100% |
| FQ4 2024 (Dec 2024) | $0B | $1.53B | $1525.3M | 100% |
| FQ3 2024 (Sep 2024) | $0B | $1.58B | $1584.4M | 100% |
| FQ2 2024 (Jun 2024) | $0B | $1.53B | $1532.5M | 100% |
| FQ1 2024 (Mar 2024) | $0B | $1.49B | $1487.9M | 100% |
| FQ4 2023 (Dec 2023) | $0B | $1.44B | $1439.3M | 100% |
CME Ratings Summary
CME Quant Ranking
